Abstract 11651: Effect of Combination Lipid Therapy on Incident Atrial Fibrillation or its Electrocardiographic Surrogate in the Action to Control Cardiovascular Risk in Diabetes Lipid (ACCORD Lipid) Trial

Introduction: Atrial fibrillation (AF) is associated with increased cardiovascular disease (CVD) risk in patients with type 2 diabetes (DM). Observational studies have suggested that higher HDL and lower triglycerides are associated with lower AF risk. Hypothesis: We hypothesized that raising HDL and lowering triglycerides will reduce AF incidence in patients with DM. As such, we compared combination lipid therapy with simvastatin and fenofibrate vs. simvastatin alone in relation to incidence of AF or its established ECG surrogate, P-wave indices (PWI), in patients with DM. Methods: We analyzed data from the Action to Control Cardiovascular Risk in Diabetes Lipid (ACCORD Lipid) trial (Jan 2001-June 2009), a randomized controlled blinded trial of patients with DM and who were aged 40–79 years with CVD or aged 55–79 years with subclinical CVD or >2 CVD risk factors. Patients were randomized to receive simvastatin plus placebo vs. simvastatin plus fenofibrate. Dosing of simvastatin and fenofibrate was based ...